It can be seen that EGFR exisits a critical role in the pathogenesis of STZ-induced myocardial injury and ROS changes in diabetes, indicating that EGFR may be a underlying target for the therapy of diabetic cardiomyopathy (96). Here, EGFR is linked to diabetic cardiomyopathy.